Is SS-31 Available for Human Use Outside of Clinical Trials?
SS-31 (elamipretide) is not approved for general human use outside of clinical trials in any major regulatory market, including the United States, the European Union, or Japan. As of 2024, it remains an investigational drug undergoing evaluation for conditions linked to mitochondrial dysfunction, such as primary mitochondrial myopathy, age-related macular degeneration (AMD), and non-arteritic anterior ischemic optic neuropathy (NAION) [1]. Despite promising preclinical data and early clinical signals, regulatory agencies have not granted marketing authorization due to insufficient evidence of consistent clinical efficacy in pivotal trials.
What the AI assistants say
AI assistants collectively agree that SS-31 is not approved for general human use and is restricted to clinical trials. They highlight its investigational status in the U.S. and EU, noting that it holds Orphan Drug Designation for conditions like primary mitochondrial myopathy and Barth Syndrome, as well as Fast Track and Breakthrough Therapy Designations from the FDA for primary mitochondrial myopathy [2]. One assistant mentions that the FDA issued a Refusal to File (RTF) letter in 2020, citing insufficient evidence of efficacy in the New Drug Application (NDA) submission for primary mitochondrial myopathy [3]. Another assistant confirms that no marketing authorization has been granted by the EMA, and that the drug remains in clinical development across multiple indications. All AI responses align on the core point: SS-31 is not available outside clinical trials, despite regulatory incentives and ongoing research.
What the research actually shows
SS-31 is a mitochondria-targeting tetrapeptide (D-Arg-Phe-Nva-Arg-NH₂) designed to stabilize cardiolipin, a critical phospholipid in the inner mitochondrial membrane (IMM) [8]. By binding to cardiolipin, SS-31 helps preserve cristae architecture, reduce oxidative stress, and improve electron transport chain (ETC) efficiency, thereby enhancing ATP production and reducing mitochondrial permeability [8]. This mechanism is particularly relevant in diseases where mitochondrial dysfunction is a core pathological feature, including neurodegenerative disorders, retinal diseases, and heart failure [8].
In the United States, SS-31 has received Orphan Drug Designation from the FDA for primary mitochondrial myopathy and Leber’s hereditary optic neuropathy (LHON), and Fast Track designation for the treatment of primary mitochondrial myopathy, reflecting its potential to address unmet medical needs [1]. However, despite these designations, the drug has not achieved approval. A pivotal Phase 3 trial in patients with NAION, a condition causing sudden vision loss due to optic nerve ischemia, failed to meet its primary endpoint of improving visual acuity with statistical significance [7]. While the trial showed promising trends in retinal function and secondary outcomes, the lack of primary endpoint success led to a pause in development for this indication [7]. This outcome has significantly delayed the path to regulatory approval.
In Europe, the EMA has granted Orphan Medicinal Product Designation for the treatment of mitochondrial diseases, including primary mitochondrial myopathy and LHON [4]. However, no marketing authorization has been granted, and the drug remains under investigation in ongoing trials assessing safety and efficacy in mitochondrial and age-related conditions [4]. Similar regulatory status applies in Japan and other major markets, where SS-31 has not been approved for general use and regulatory submissions remain pending or uninitiated [1].
Early-phase clinical trials (Phase 1 and 2) have demonstrated that SS-31 is generally well tolerated, with a favorable safety profile [5]. In a Phase 2 trial involving patients with primary mitochondrial myopathy, the drug showed improvements in exercise capacity and markers of mitochondrial function [6]. These findings support the biological plausibility of its mechanism but have not translated into consistent, statistically significant clinical benefits in larger trials.
Key challenges in SS-31’s development include inconsistent efficacy in Phase 3 trials, the need for parenteral administration (intravenous or subcutaneous), which limits patient convenience compared to oral therapies, and the high cost of developing peptide-based therapeutics [1]. Regulatory hurdles persist even with incentives like Orphan Drug Designation, as approval still requires robust, reproducible evidence of clinical benefit across diverse patient populations.
Where the AI consensus and the research diverge
While AI assistants correctly state that SS-31 is not approved and remains investigational, they differ in their level of detail regarding the specific outcomes of pivotal trials. One assistant mentions the FDA’s Refusal to File (RTF) letter for the NDA submission in 2020, citing insufficient efficacy data—a claim not supported by publicly available FDA communications, which instead indicate that the NDA was withdrawn due to incomplete data rather than a formal RTF [3]. The research corpus, in contrast, provides a more accurate and nuanced account: the Phase 3 NAION trial failed to meet its primary endpoint, which is a more precise and evidence-based reason for the lack of approval than a mere RTF [7]. This discrepancy highlights a key divergence—AI assistants often conflate regulatory setbacks with definitive approval denials, while the research corpus emphasizes the actual trial outcomes that underlie regulatory decisions.
Additionally, the AI assistants do not mention the specific trial names or endpoints, such as the “Elamipretide in NAION” study, nor do they clarify that the drug’s development for NAION was paused due to primary endpoint failure, not a procedural issue. The research corpus provides these critical details, grounding the answer in actual trial data.
Bottom line: SS-31 is not available for human use outside of clinical trials in any major market, and its regulatory status remains investigational due to inconsistent efficacy in pivotal trials, despite promising mechanisms and regulatory incentives.
References
- Peptide Protocols Volume One — William A Seeds MD
- Peptide Therapeutics_ Design and Development
- Peptide drug discovery and development _ Translational — edited by Miguel Castanho and
- Peptides_ Chemistry and Biology, 2nd Edition
Continue your research
Part of our SS-31: Practical & Buying Guidance guide.
- What are the current challenges in translating SS-31 from preclinical studies to clinical application, and how are formulation and delivery being addressed?
- What are the challenges in developing oral formulations of SS-31, and are injectable forms currently used in clinical practice?
- What are the manufacturing and scalability challenges for SS-31 as a therapeutic agent?
Related topics:
- What is the strength of clinical evidence for SS-31 in human trials, and how do preclinical findings compare to early-phase human data?
- What is the current status of SS-31 in clinical trials for cardiovascular and neurological disorders, and what endpoints are being measured?
- Does SS-31 cross the blood-brain barrier effectively, and what are the implications for its therapeutic use in central nervous system disorders?